Regeneron Pharmaceuticals' Equity Average rose 602.46% to $31.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $31.1 billion, marking a year-over-year increase of 602.46%. This contributed to the annual value of $30.3 billion for FY2025, which is 955.02% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Equity Average stood at $31.1 billion for Q4 2025, which was up 602.46% from $30.4 billion recorded in Q3 2025.
Regeneron Pharmaceuticals' 5-year Equity Average high stood at $31.1 billion for Q4 2025, and its period low was $11.5 billion during Q1 2021.
For the 5-year period, Regeneron Pharmaceuticals' Equity Average averaged around $23.6 billion, with its median value being $24.1 billion (2023).
Examining YoY changes over the last 5 years, Regeneron Pharmaceuticals' Equity Average showed a top increase of 7033.3% in 2021 and a maximum decrease of 94.91% in 2021.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Equity Average stood at $18.0 billion in 2021, then rose by 22.42% to $22.1 billion in 2022, then rose by 15.36% to $25.4 billion in 2023, then increased by 15.33% to $29.3 billion in 2024, then grew by 6.02% to $31.1 billion in 2025.
Its last three reported values are $31.1 billion in Q4 2025, $30.4 billion for Q3 2025, and $29.7 billion during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value